AACE MENA 2025-CGM Use in People With and Without Diabetes

Video Transcription

Video Summary

The speaker discusses continuous glucose monitoring (CGM) technology in both diabetic and non-diabetic individuals, emphasizing its evolution and clinical use. CGM offers continuous, real-time glucose data, providing a comprehensive view of glucose patterns beyond traditional point measurements like HbA1c. In type 1 diabetes, CGM is standard care, improving glycemic control and quality of life. For type 2 diabetes, benefits are strongest in insulin-intensive treatments, aiding medication adjustments and lifestyle adherence, though broader use faces barriers such as cost, device discomfort, and data overload. CGM shows promise in gestational diabetes, enhancing maternal and neonatal outcomes. In non-diabetic populations, CGM reveals individual glucose variability and helps promote healthier behaviors, though evidence on long-term benefits and cost-effectiveness remains limited. Overall, CGM is transformative but requires evidence-based, ethical application and addressing implementation challenges to maximize its potential across diverse patient groups and settings.

Keywords

continuous glucose monitoring

CGM technology

type 1 diabetes

type 2 diabetes

gestational diabetes

non-diabetic glucose variability